Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (Nasdaq: CTKB) is a cell analysis solutions company focused on high-parameter flow cytometry using its patented Full Spectrum Profiling™ (FSP®) technology. This news page aggregates coverage of Cytek’s announcements so readers can follow developments related to its instruments, reagents, services and corporate activities.
Company press releases frequently address financial results and outlook, including quarterly revenue performance, recurring revenue trends from service and reagent businesses, and updates on installed instrument base. Cytek also issues news when it provides preliminary revenue expectations or reaffirms full-year guidance, and these items are often accompanied by Form 8-K filings summarizing results of operations.
Another major category of CTKB news involves product and technology updates. Recent communications have highlighted the launch of the Cytek Aurora™ Evo full spectrum flow cytometer, enhancements to small particle detection, and initiatives to expand access to advanced cytometry tools through instrument awards and research grants. The company also reports on the use of its FSP systems in peer-reviewed research and at scientific meetings.
Investors and researchers will also find corporate and recognition news, such as Cytek’s inclusion on TIME’s 2026 list of America’s Growth Leaders, expansion of its European headquarters in Amsterdam, and participation in healthcare and investor conferences hosted by organizations including UBS, Morgan Stanley, Stephens and Piper Sandler. Updates on collaborations with groups like the International Society for Advancement of Cytometry (ISAC) and presence at clinical cytometry conferences such as ESCCA and ICCS are also covered.
By reviewing CTKB news, users can track how Cytek communicates its financial performance, product evolution, geographic expansion and engagement with the scientific and investment communities over time.
Cytek Biosciences (Nasdaq: CTKB) announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company expects full-year 2025 revenue of approximately $201 million and Q4 2025 revenue of approximately $62 million, representing Q4 growth of +8% year-over-year and +19% quarter-over-quarter. Management cited strength in Services, Reagents and Asia Pacific instrument revenue and a return to positive instrument growth in EMEA. Results are preliminary and subject to year-end close and audit. Cytek will report audited results and provide 2026 guidance near the end of February 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Cytek Biosciences (Nasdaq: CTKB) was named to TIME’s 2026 America’s Growth Leaders list, compiled with Statista, recognizing top U.S. public companies for five‑year growth, financial stability, and stock performance. The announcement highlights Cytek’s sustained business expansion and its Full Spectrum Profiling™ (FSP®) flow cytometry platform, which is cited in more than 3,200 peer‑reviewed publications. The recognition underscores the company’s mission to expand access to high‑parameter cell analysis and its role in research areas including cancer, cell and gene therapy, vaccines, and emerging disease response.
Cytek Biosciences (Nasdaq: CTKB) announced on November 6, 2025 that its Cytek Muse Micro cell analyzer won Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.
The award recognizes the Muse Micro as an affordable, compact, and intuitive flow cytometry platform that builds on the legacy of the original Guava Muse system. Applications cited include cell counting, viability, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis. The company said the system aims to lower technical and financial barriers for smaller labs and resource-limited facilities.
Cytek Biosciences (Nasdaq: CTKB) announced investor conference participation and investor meetings in November–December 2025. Key events include UBS Global Healthcare Conference (Palm Beach) with 1x1 meetings on Nov 11, 2025, a Stephens NASH25 fireside chat on Nov 19, 2025 at 9:00 a.m. PT / 12:00 p.m. ET, and a Piper Sandler 37th Annual Healthcare fireside chat on Dec 3, 2025 at 6:00 a.m. PT / 9:00 a.m. ET.
Live and archived webcasts for the Stephens and Piper Sandler presentations will be available on the company investor website at investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $52.3M, up 2% year-over-year, with total installed base at 3,456 instruments (added 161 units). Total recurring revenue rose 19% and revenue from biotech/pharma/CRO customers grew 14%. GAAP gross profit was $27.6M and GAAP gross margin was 53% (adjusted gross margin 55% vs 60% prior year). Operating expenses increased 10% and G&A rose 47% due to litigation-related costs and a $0.7M one-time write-off. Net loss was $5.5M versus net income of $0.9M in Q3 2024. Adjusted EBITDA was $2.5M. Cash and marketable securities totaled $261.7M. Full‑year 2025 revenue guidance reaffirmed at $196M–$205M.
Cytek Biosciences (NASDAQ: CTKB) announced a two-part initiative to expand global access to flow cytometry, partnering with the International Society for Advancement of Cytometry (ISAC).
Phase one awards a three-laser Cytek Northern Lights full spectrum flow cytometer to an eligible lab. Phase two will launch a merit-based research grant program overseen by Cytek’s scientific advisory board, expected to debut in conjunction with CYTO 2026. The company cited prior collaboration with ISAC, including a donated Northern Lights system to a laboratory in Salta, Argentina, as an example of impact.
Cytek framed the effort as expanding scientific equity by supporting under-resourced labs and enabling broader access to high-parameter immune monitoring and translational research.
Cytek Biosciences (Nasdaq: CTKB) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.
The company said management will host a webcasted conference call on November 5, 2025 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook. Live audio will be available on the Investors section of the company website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) announced it has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District effective Oct 15, 2025. The site expands Cytek's European footprint by more than 40% and houses offices, an enlarged warehouse, and a dedicated customer service and training center with a fully functional lab for hands-on training on Cytek's Full Spectrum Profiling™ (FSP®) technology.
The company cited strong reagent-business performance as a key driver and has transitioned warehouse operations in-house to improve quality control, operational agility, and turnaround times across EMEA.
Cytek Biosciences (NASDAQ:CTKB), a leader in spectral flow cytometry, will showcase its advanced cell analysis solutions at two major clinical conferences: ESCCA 2025 (September 17-20 in Montpellier, France) and ICCS 2025 (September 28-30 in Philadelphia).
The company's Full Spectrum Profiling™ (FSP®) technology has gained significant traction, with over 2,800 peer-reviewed publications citing its use. The technology enables profiling of more than 40 markers in a single tube, enhancing efficiency and reducing analysis time.
At both conferences, experts will present workshops on integrating spectral flow cytometry with machine learning for improved leukemia and lymphoma diagnosis, demonstrating the technology's practical applications in clinical settings.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.
The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
